Metlifecare Limited — Director's Dealing 2017

Oct 12, 2017

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

ToNZX Limited andASX
Name of listedissuer:	MetlifecareLimited
Date this disclosuremade:	12October 2017
Date of last disclosure:	12October 2016

A. Director or senior manager giving disclosure

A. Director or senior manager giving disclosure
Full name(s):	Glen Robert Sowry
Name of listedissuer:	MetlifecareLimited
Name of related body corporate (ifapplicable):	N/A
Position heldin listedissuer:	Chief Executive Officer

B. Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class ofaffected quotedfinancialproducts:	Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Owner (as a participant in Metlifecare Limited's senior executive restricted share plan)
For that relevant interest-
Number heldinclass before acquisitionordisposal:	31,045
Number heldinclass afteracquisitionordisposal:	64,277
Currentregisteredholder(s):	N/A
Registered holder(s) once transfers are registered:	Metlifecare LTIP Trustee Limited

C. Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

applicable)
Type ofaffected derivative:	N/A
Class ofunderlyingfinancialproducts:	N/A
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date ofthe derivative (ifany):	N/A
Expiry date ofthe derivative (ifany):	N/A
The price specifiedinthe terms ofthe derivative (ifany):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
For that derivative,-
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, thenature oftherelevantinterestinthe derivative:	N/A

D. Details of transactions giving rise to acquisition or disposal

Total numberoftransactions towhich noticerelates:	One
Details of transactions requiring disclosure-
Date oftransaction:	12October 2017
Nature of transaction:	Issue of shares further to Metlifecare Limited's senior executive restricted share plan
Name of any other party or parties to the transaction (if known):	Metlifecare Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	$193,048.01
Numberof financialproducts towhichthe transaction related:	33,232
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—
Whether relevant interests were acquired or disposed of during a closed period:	The ordinary shares were issued as part of Metlifecare Limited's senior executive restricted share plan, therefore, Metlifecare Limited’s financial products trading policy did not apply to the allotment. In any case, the shares are not issued during a closed period
Whether prior written clearance was provided to allow the acquisitionordisposalto proceed during the closed period:	N/A
Date ofthe prior writtenclearance (ifany):	N/A

E. Summary of other relevant interests after acquisition or disposal:

Class ofquotedfinancialproducts:	N/A
Nature of relevantinterest:	N/A
For that relevant interest,-
Number heldinclass:	N/A
Currentregisteredholder(s):	N/A
For a derivative relevant interest,-
Type ofderivative:	N/A
Details of derivative-
The notional value of the derivative (if any) or the notional amount ofunderlyingfinancialproducts (ifany):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price's specified terms (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
For that derivative relevant interest,-
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, thenature oftherelevantinterestinthe derivative:	N/A

F. Certification

F. Certification
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom itismade.
Signature ofdirectororofficer:
Date ofsignature:
or
Signature of person authorised to sign on behalf of director or officer:
Date ofsignature:	12October 2017
Name and title of authorised person:	Andrew Peskett, General Counsel and Company Secretary